3023.0: Monday, October 22, 2001 - 1:15 PM

Abstract #28674

Prevalence corrected prostate cancer incidence rates and trends

Ray M Merrill, PhD, MPH, Brigham Young University, Provo, UT 84602, 801-378-9788, ray_merrill@byu.edu

A correction is made of prostate cancer incidence rates based on data from the Surveillance, Epidemiology, and End Results (SEER) Program of the United States National Cancer Institute. Unlike conventional incidence rates reported by SEER, corrected rates remove from the population the estimated number already having been diagnosed with the disease. The corrected rates reflect the average prostate cancer risk for men in the at-risk population. Because of the high incidence and relatively good survival of prostate cancer, the prevalence of this disease is higher than that of any other cancer in men. Corrected prostate cancer incidence rates were higher in magnitude and tended to have more extreme trends than the conventional rates, more so in older age groups. For example, in 1997 the corrected rates were 3.8% higher in cases aged 60-69, 9.3% higher in cases aged 70-79, and 13.1% higher in cases aged 80+. Based on the proportion of diagnosed cases undergoing a radical prostatectomy or other cancer-directed surgery and the resulting costs, underestimation of prostate cancer treatment involving surgery is above 15.6 million dollars. Therefore, national estimates of prostate cancer cases based on conventional rates underestimate the cancer burden and may have implications in terms of health care planning and resource allocation.

Learning Objectives: At the conclusion of the session, the participant (learner) in this session will be able to: 1.Learn how the age-adjusted prostate cancer incidence rate may be corrected for prevalent cases of the disease in the population. 2.Articulate the proceedure for correcting prostate cancer incidence rates. 3.Have a basic understanding on how to correct SEER-based site-specific cancer incidence rates.

Keywords: Surveillance, Aging

Presenting author's disclosure statement:
Organization/institution whose products or services will be discussed: None
I do not have any significant financial interest/arrangement or affiliation with any organization/institution whose products or services are being discussed in this session.

The 129th Annual Meeting of APHA